Bayer Stock Races Ahead on Twin Catalysts, but Frayed Technicals Signal a Pause May Be Due

Bayer shares rally 42.6% after Supreme Court blocks Roundup lawsuits and Apollo invests €3B in contraceptive unit, but overbought RSI signals caution.

The past month has been nothing short of extraordinary for Bayer’s shareholders. Since late June, the stock has surged 42.6%, propelling the shares to within 6.83% of their 52-week high of €53.86, which was struck on July 3. Yet the immediate picture is more nuanced: on Friday, the shares closed at €50.18, down 1.03% on the day and 5.39% lower over the past week. That weekly retreat, combined with a relative strength index (RSI) of 70.4 — comfortably into overbought territory — suggests that the market is now weighing how much of the recent good news is already priced in.

The twin impulses behind the rally are a landmark legal victory and a major capital injection. Late last month, the U.S. Supreme Court ruled 7-2 that Bayer cannot be sued under state law for failing to warn about cancer risks linked to its Roundup herbicide containing glyphosate. The decision immediately defanged thousands of pending cases and cleared a cloud that has hung over the stock for years. Then, on Friday, Bayer announced it had struck a €3 billion deal with asset manager Apollo to bring fresh equity into the group, buying a minority stake in its long-acting reversible contraceptive (LARC) business.

The Apollo transaction is structured through a newly created entity that houses the LARC unit. Funds and affiliates managed by Apollo will take a minority position, while Bayer retains majority control and continues to run the business operationally. The company stressed that LARC remains a core part of its pharmaceutical division and will stay fully consolidated. Closing is expected in the third quarter of 2026, pending approval from competition authorities. For Bayer, the deal provides much-needed financial breathing room to address upcoming bond maturities and the ongoing costs of legacy U.S. litigation, without altering its long-term strategy.

The Supreme Court ruling, meanwhile, removes the most acute legal threat. The justices held that federal law preempts state-law failure-to-warn claims, meaning Bayer cannot be held liable for not flagging cancer dangers that federal regulators had already deemed adequately addressed. Bayer itself called the decision "helpful" and expects that both pending and future cases of this nature will be dismissed. But the legal picture is not entirely tidy. A separate multibillion-dollar class-action settlement involving glyphosate cases has been sent back to a court in Missouri by a federal judge for further review — not a reversal, but not a clean closure either. Moreover, Bayer has set aside tens of billions of euros in provisions over the years and continues to defend some claims in court.

On the technical front, the speed of the rally has left the stock stretched. At Friday’s close, the share price traded nearly 25% above its 50-day moving average of €40.16 and more than 33% above the 200-day average of €37.68. The annualized 30-day volatility sits at 61.88%, underscoring the elevated level of nervousness among investors. A pullback toward that €40 handle is not out of the question if sentiment shifts, especially given that some market participants are already taking profits after the Supreme Court?fueled spike.

The next concrete test for bulls will come on August 7, 2026, when Bayer reports second-quarter results. Management reaffirmed its full-year guidance in April, calling for stable revenues at constant currencies and mid-single-digit growth in adjusted EBITDA. Investors will be looking for details on cash flow and net debt reduction to gauge whether the operational momentum can sustain the re?rating that the stock has enjoyed. Should the numbers disappoint, or if fresh negative headlines emerge from the Missouri settlement review, the technical overhang could trigger a sharper correction.

For now, Bayer finds itself in a rare moment of dual optimism: legal clarity and a capital infusion that removes near-term financing constraints. The challenge is that the share price has already moved a long way in a short time. Whether the stock can consolidate at these levels — or even push higher — depends on the company delivering concrete financial progress in the coming weeks. The August earnings report will be the first real litmus test for a rally that has yet to prove it has fundamental legs beyond the courtroom and the balance sheet.